Dizal (Jiangsu) Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Dizal (Jiangsu) Pharmaceutical wird ein Gewinn- und Umsatzwachstum von 58.9% bzw. 45.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 59.1% pro Jahr wachsen soll.

Wichtige Informationen

58.9%

Wachstumsrate der Gewinne

59.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	43.1%
Wachstumsrate der Einnahmen	45.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

Gewinn- und Umsatzwachstumsprognosen

SHSE:688192 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,835	-73	-40	75	5
12/31/2025	947	-561	-648	-490	5
12/31/2024	456	-858	-1,053	-826	5
9/30/2024	390	-837	-862	-762	N/A
6/30/2024	295	-938	-869	-829	N/A
3/31/2024	173	-1,092	-929	-891	N/A
12/31/2023	91	-1,108	-1,000	-968	N/A
9/30/2023	40	-1,055	-885	-851	N/A
6/30/2023	N/A	-905	-801	-763	N/A
3/31/2023	N/A	-794	-714	-634	N/A
12/31/2022	N/A	-736	-677	-603	N/A
9/30/2022	4	-714	-648	-575	N/A
6/30/2022	7	-716	-600	-532	N/A
3/31/2022	10	-716	-549	-537	N/A
12/31/2021	10	-670	-501	-492	N/A
9/30/2021	11	-593	-434	-429	N/A
12/31/2020	28	-587	-622	-410	N/A
12/31/2019	41	-446	-379	-366	N/A
12/31/2018	39	-174	-149	-136	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 688192 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 688192 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 688192 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 688192Die Einnahmen des Unternehmens (45.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 688192Die Einnahmen des Unternehmens (45.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 688192 in 3 Jahren voraussichtlich hoch sein wird

Dizal (Jiangsu) Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.4% to CN¥56.00

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 13%

Price target increased by 11% to CN¥56.42

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Price target increased by 7.4% to CN¥56.00

Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Consensus revenue estimates decrease by 12%

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

New minor risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Consensus EPS estimates fall by 13%

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Price target increased by 11% to CN¥56.42

Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

Less than half of directors are independent

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken